Tag: M.W:500-600

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

The solids thus obtained were redissolved in DMF andsuccessively treated with HOBt (45.9 mg, 0.300 mmol), 2-(1,4,7,10-tetraaza-4,7,10-tris{[(tert-butyl)oxycarbonyl]methyl}-cyclododecyl)acetic acid (172 mg, 0.300 mmol), i-Pr2NEt(105 muL, 0.600 mmol) and HBTU (1 14 mg, 0.300 mmol) at 22 C.After 0.25 h, complete acylation was observed; only trace amounts ofregioisomeric and dimericproducts formed. The resulting solution was partitioned between EtOAcand H2O (50 mL each) with transfer to a separatory funnel. Thelayers separated and the aqueous layer washed with EtOAc (2 x 50 mL). The EtOAcsolution was further washed with 0.1 M NaOH (3 x 50 mL) and saturated aqueousNaCl (3 x 50 mL each), then dried over MgSO4, filtered andconcentrated in vacuo to a pale yellow oil that was used without furtherpurification in the subsequent deprotection step., 137076-54-1

137076-54-1 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid 11606627, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Lantheus Medical Imaging, Inc.; Sesady, Richard Al; Harris, Thomas?D; Robinson, Simon P; Ruby, Richard J; Jijimon, Edward H; Yallamanchilli, Padmaja; Cosebio, David S; (97 pag.)KR101595324; (2016); B1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

500 mg of compound 17-3 and 1.3 g of compound 17-1 were dissolved in 20 mL of acetonitrile, 680 mg of potassium carbonate was added, and the mixture was heated to reflux overnight, cooled to room temperature, filtered, and concentrated. Mix sample was dissolved in dichloromethane, separated by column chromatography (PE: EA = 20: 1-1: 1) to give a colorless waxy compound 17-4 500mg, Yield: 39.6%., 170161-27-0

As the paragraph descriping shows that 170161-27-0 is playing an increasingly important role.

Reference£º
Patent; Shenzhen Xiaxiwan Pharmaceutical Technology Co., Ltd.; Qi Fei; Xia Junxia; Zhang Zaijun; Wang Liang; (27 pag.)CN109988153; (2019); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1351279-73-6,4,4′,4”,4”’-(Ethene-1,1,2,2-tetrayl)tetrabenzoic acid,as a common compound, the synthetic route is as follows.

Weigh H4TCPE (30mg, 0.06mmol), Ni(NO3)2?6H2O (166mg, 0.57mmol) and L-Pro (12mg, 0.1mmol) was dissolved in 2mL water and 4mL N, N- dimethylformamide mixed solution, stirred for 12 hours until homogeneity, placed in an oven, heated at 100 deg. C for 72 hours, the oven was turned off, cooled to room temperature, a green bulk crystal was produced, filtered and dried, yield 10%.

1351279-73-6, 1351279-73-6 4,4′,4”,4”’-(Ethene-1,1,2,2-tetrayl)tetrabenzoic acid 101553689, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Dalian University of Technology; Duan, Chunying; Zhou, Zhen; Lu, Yang; He, Cheng; (12 pag.)CN105348071; (2016); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

General procedure: The y-carbaldehyde intermediates (29.0 muL, 500 mumol) were added to a solution of tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (35.7 mg, 71.0 mumol) in MeOH (1.0 mL) and AcOH (100 L) under N2 and stirred for 2 h at room temperature. NaBH3CN (8.90 mg, 142 mumol) was added slowly to the reaction mixture and stirred at room temperature for 24 h. The reaction mixture was poured into saturated NaHCO3, extracted with EtOAc and dried with MgSO4. The organic layer was then washed with water and brine, dried with MgSO4 and concentrated under reduced pressure to obtain the corresponding tri-N-Boc-protected amine intermediates (68.9 mg), which were used in the next step without purification. The intermediates were then dissolved in CHCl3 (2.50 mL) and treated with 95% aqueous TFA (2.50 mL) at 0 C for 6 h. The mixture was concentrated under reduced pressure and purified by preparative HPLC to obtain the desired compounds 6-12.

170161-27-0, 170161-27-0 Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 10940041, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Sakyiamah, Maxwell M.; Kobayakawa, Takuya; Fujino, Masayuki; Konno, Makoto; Narumi, Tetsuo; Tanaka, Tomohiro; Nomura, Wataru; Yamamoto, Naoki; Murakami, Tsutomu; Tamamura, Hirokazu; Bioorganic and Medicinal Chemistry; vol. 27; 6; (2019); p. 1130 – 1138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.135616-36-3,(S,S)-(+)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine,as a common compound, the synthetic route is as follows.

Reference Example 1 [(R,R)-N,N’-bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine] (hereinafter, referred to as L3 when it is a ligand of a complex) (10.9 g, 20.0 mmol) was dissolved in dichloromethane (80mL), the solution was added to a methanol solution (80 mL) of cobalt acetate tetrahydrate (5.98 g, 24.0 mmol), the mixture was stirred at room temperature for 15 minutes, and as a result, a red solid was precipitated. After stirred at 0 C. for 30 minutes, the red solid was collected and dried to obtain Co(L3) (11.6 g, red solid) (yield: 96%)., 135616-36-3

The synthetic route of 135616-36-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Japan Science and Technology Agency; Takasago International Corporation; US2006/173210; (2006); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

(1) To a solution of tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (24.8 mg) in DMF (0.2 mL) and DIEA (17 muL), a solution of HBTU (17.0 mg) in DMF (100 muL) was added, then the mixture was added to a solution of compound (L7) (13.1 mg) in DMF (200 muL) and DIEA (10 muL), and the resulting mixture was stirred at room temperature for 1 hour. Water (200 muL) was added thereto, and the mixture was purified by preparative HPLC to obtain compound (M1) (12.3 mg). LC/MS (SunFire) rt (min): 11.05 MS (ESI, m/z): 730.95 [M+2H]2+, 1459.05 [M-H]-

137076-54-1, The synthetic route of 137076-54-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; FUJIFILM Corporation; FUJIFILM RI PHARMA CO., LTD.; FUKUNAGA, Hirofumi; DOZONO, Hiroyuki; HINO, Akihiro; OSHIKIRI, Shinobu; NAGANO, Akio; (99 pag.)US2016/199520; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

(11) To a solution of tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (25.1 mg) in DMF (150 muL) and DIEA (30 muL), a solution of HBTU (16.7 mg) in DMF (150 muL) was added, then the mixture was added to a solution of compound (Q10) (13.9 mg) in DMF (400 muL) and DIEA (20 muL), and the resulting mixture was stirred at room temperature for 45 minutes. Water (300 muL) was added thereto, and the mixture was purified by preparative HPLC to obtain compound (Q11) (11.1 mg). HPLC (SunFire) rt (min): 10.80 LC/MS (ACQUITY) rt (min): 1.24 MS (ESI, m/z): 1504.6 [M+H]+, 1502.6 [M-H]-, 137076-54-1

The synthetic route of 137076-54-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; FUJIFILM Corporation; FUJIFILM RI PHARMA CO., LTD.; FUKUNAGA, Hirofumi; DOZONO, Hiroyuki; HINO, Akihiro; OSHIKIRI, Shinobu; NAGANO, Akio; (99 pag.)US2016/199520; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

500 mg of compound 19-3 and 1.3 g of compound 17-1 were dissolved in 20 mL of acetonitrile, and 680 mg of potassium carbonate was added thereto, and the mixture was heated to reflux overnight, cooled to room temperature, filtered, and the filtrate was concentrated and evaporated. Column chromatography (PE: EA = 20: 1-1: 1) to give a colorless waxy compound 19-4 510mg, Yield: 40.4%.

170161-27-0, The synthetic route of 170161-27-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Shenzhen Xiaxiwan Pharmaceutical Technology Co., Ltd.; Qi Fei; Xia Junxia; Zhang Zaijun; Wang Liang; (27 pag.)CN109988153; (2019); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

(7) To a mixture of compound (K6) (84.3 mg), tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (60.7 mg), DMF (1 mL), and DIEA (50 muL), HBTU (40.2 mg) was added, and the resulting mixture was stirred at room temperature for 30 minutes. Water (1 mL), methanol (0.5 mL), and formic acid (200 muL) were added thereto, and the mixture was purified by preparative HPLC to obtain compound (K7) (61.9 mg). LC/MS (ACQUITY) rt (min): 1.12 MS (ESI, m/z): 677.4 [M+2H]2+, 1351.3 [M-H]-, 137076-54-1

137076-54-1 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid 11606627, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; FUJIFILM Corporation; FUJIFILM RI PHARMA CO., LTD.; FUKUNAGA, Hirofumi; DOZONO, Hiroyuki; HINO, Akihiro; OSHIKIRI, Shinobu; NAGANO, Akio; (99 pag.)US2016/199520; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

137076-54-1, To a solution of product 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid (572.7 mg, 1 mmol) in dry DMF (15 ml), amino-maleinnide 137 (483.3 mg, 1 mmol) was added with HATU (272 mg, 1 .4 mmol) and DIPEA (360 mul, 1.84 mmol). The mixture was stirred overnight at room temperature. After removing the solvent under the vacuum, the crude product was purified by flash chromatography on silica gel (CH2Cl2/MeOH, 90:10) to give compound tri-tert-butyl 2,2′,2″-(10-(2-((2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate as a white foam (396 mg, 57 %). Rf : 0.3 (CH2Cl2/MeOH, 90:10). 1H NMR (300MHz, CDCl3) delta 8.30 (b, 1 H, NH), 6.86 (s,2H, H6′), 3.78-3.54 (br, 4H, H3′, H4′), 3.54 (br, 4H, H13, H1′), 3.48 (br, 4H, H8), 3.09-2.99 (m, 8H, H2, H3), 2.97-2.86 (m, 8H, H5, H6), 1 .46 (s, 18H, H12), 1 .45 (s, 9H, H17). 13C NMR (75MHz, CDCl3) delta 171 .6 (C2′), 171 .0 (C5′), 170.4 (C9, C14), 134.2 (C6′), 81 .5 (C16), 81 .3 (C11), 57.8 (C1′), 55.7-55.2 (C8, C13), 54.1 – 51 .5 (C2, C3), 51 .0-48.9 (C5, C6), 38.0 (C4′), 32.7 (C3′), 27.8 (C17), 27.6 (C12). MS (ESI) : m/z 695 [M + H]+.

As the paragraph descriping shows that 137076-54-1 is playing an increasingly important role.

Reference£º
Patent; INSTITUT CURIE; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6); FLORENT, Jean-Claude; AIT SARKOUH, Rafik; JOHANNES, Ludger; SCHMIDT, Frederic; OBERLEITNER, Birgit; DRANSART, Estelle; SEMETEY, Vincent; WO2014/86942; (2014); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI